Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Dodick

Showing results (251-260 of 365) with videos related to

Pageof 37
Sort By:
Headache|October 4, 2025
Navigating the patient journey in migraine prevention: An American Migraine Foundation position paperLawrence C Newman, Christine Lay, Richard B Lipton, et al.
Headache|December 28, 2021
Development and validation of a novel patient-reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine DiaryRichard B Lipton, Pranav Gandhi, Jonathan Stokes, et al.
European Journal of Neurology|January 5, 2021
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trialMessoud Ashina, Peter J Goadsby, Uwe Reuter, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|May 1, 2022
Sleep restriction alters cortical inhibition in migraine: A transcranial magnetic stimulation studyMartin Syvertsen Mykland, Martin Uglem, Jan Petter Neverdahl, et al.
Headache|October 27, 2018
Improving Medical Communication in Migraine Management: A Modified Delphi Study to Develop a Digital Migraine TrackerDavid W Dodick, Stewart J Tepper, Richard B Lipton, et al.
JAMA|May 26, 2018
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical TrialDavid W Dodick, Stephen D Silberstein, Marcelo E Bigal, et al.
Nature Reviews. Disease Primers|January 14, 2022
MigraineMichel D Ferrari, Peter J Goadsby, Rami Burstein, et al.
Lancet (London, England)|November 18, 2023
Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USADavid W Dodick, Peter J Goadsby, Todd J Schwedt, et al.
Headache|September 30, 2021
Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing dataDavid W Dodick, Stewart J Tepper, Jessica Ailani, et al.
Headache|February 20, 2020
Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and IIDavid W Dodick, Richard B Lipton, Jessica Ailani, et al.
Pageof 37

Showing results (251-260 of 365) with videos related to

Sort By:
Pageof 37
Headache|October 4, 2025
Navigating the patient journey in migraine prevention: An American Migraine Foundation position paperLawrence C Newman, Christine Lay, Richard B Lipton, et al.
Headache|December 28, 2021
Development and validation of a novel patient-reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine DiaryRichard B Lipton, Pranav Gandhi, Jonathan Stokes, et al.
European Journal of Neurology|January 5, 2021
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trialMessoud Ashina, Peter J Goadsby, Uwe Reuter, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|May 1, 2022
Sleep restriction alters cortical inhibition in migraine: A transcranial magnetic stimulation studyMartin Syvertsen Mykland, Martin Uglem, Jan Petter Neverdahl, et al.
Headache|October 27, 2018
Improving Medical Communication in Migraine Management: A Modified Delphi Study to Develop a Digital Migraine TrackerDavid W Dodick, Stewart J Tepper, Richard B Lipton, et al.
JAMA|May 26, 2018
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical TrialDavid W Dodick, Stephen D Silberstein, Marcelo E Bigal, et al.
Nature Reviews. Disease Primers|January 14, 2022
MigraineMichel D Ferrari, Peter J Goadsby, Rami Burstein, et al.
Lancet (London, England)|November 18, 2023
Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USADavid W Dodick, Peter J Goadsby, Todd J Schwedt, et al.
Headache|September 30, 2021
Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing dataDavid W Dodick, Stewart J Tepper, Jessica Ailani, et al.
Headache|February 20, 2020
Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and IIDavid W Dodick, Richard B Lipton, Jessica Ailani, et al.
Pageof 37